WO2014163206A1 - Use of functional melanocytes readily differentiated from multilineage-differentiating stress-enduring (Muse) cells, distinct stem cells in human fibroblasts - Google Patents

Use of functional melanocytes readily differentiated from multilineage-differentiating stress-enduring (Muse) cells, distinct stem cells in human fibroblasts Download PDF

Info

Publication number
WO2014163206A1
WO2014163206A1 PCT/JP2014/060045 JP2014060045W WO2014163206A1 WO 2014163206 A1 WO2014163206 A1 WO 2014163206A1 JP 2014060045 W JP2014060045 W JP 2014060045W WO 2014163206 A1 WO2014163206 A1 WO 2014163206A1
Authority
WO
WIPO (PCT)
Prior art keywords
muse
cells
melanocytes
skin
cell
Prior art date
Application number
PCT/JP2014/060045
Other languages
English (en)
French (fr)
Inventor
Mari Dezawa
Kenichiro TSUCHIYAMA
Masanori Yoshida
Setsuya Aiba
Kenshi Yamasaki
Original Assignee
Clio, Inc.
Tohoku University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clio, Inc., Tohoku University filed Critical Clio, Inc.
Priority to JP2015548081A priority Critical patent/JP2016516394A/ja
Publication of WO2014163206A1 publication Critical patent/WO2014163206A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0626—Melanocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/365—Endothelin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/091—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells melanocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells

Definitions

  • the present invention relates to use of Muse- melanocytes in regenerative medicine. Specifically, the present invention provides a pharmaceutical composition comprising the Muse-melanocytes and keratinocytes, and a method of treating pigment disorder.
  • the present invention provides a pharmaceutical composition comprising the Muse-melanocytes and keratinocytes, and a method of treating pigment disorder.
  • invention is based on a finding of newly identified Muse cells in human dermal fibroblasts which are readily differentiated into functional melanocytes by using certain combinations of factors and cytokines.
  • Melanocytes produce melanin and deliver them to neighboring keratinocytes to protect the skin from ultraviolet (UV) rays (Kondo et al, 2011; Slominski et al, 2004). Melanocyte dysfunction results in a variety of pigment disorders, such as albinism and vitiligo, which cause not only cosmetic problems but also increase the risk of skin cancers due to incomplete protection from UV rays (Mabula et al, 2012) .
  • UV ultraviolet
  • Manzar et al, 2011 and the risk of tumorigenesis for both ES and iPS cells are obstacles to clinical use (Fong et al, 2010; Goldring et al, 2011; Ben-David 2011; Okita et al, 2007) .
  • MSCs Mesenchymal stem cells
  • mesenchymal tissues such as the bone marrow, dermis, fat tissue, and dental pulp, and are used for the treatment of many kinds of diseases (Sng et al, 2012; Hare et al,
  • MSCs have attracted attention because of their ability to differentiate into a broad spectrum of cells. MSCs can differentiate not only into mesodermal lineage cells, but also into ectodermal or endodermal lineage cells (Phinney et al, 2007; Pittenger et al, 1999; Dezawa et al, 2004; Sakaida et al, 2004) .
  • MSCs dental pulp stem cells
  • Muse cells normally exist in human mesenchymal cultured cells such as dermal fibroblasts and bone marrow stromal cells, and also in mesenchymal tissue, such as dermis and bone marrow. Muse cells have characteristics similar to both pluripotent stem cells and MSCs: they can be isolated by fluorescence-activated cell sorting (FACS) as cells double-positive for pluripotency [stage-specific
  • SSEA-3 embryonic antigen-3
  • ectodermal-lineage cells from a single cell.
  • Muse cells have low telomerase activity and do not form tumors in vivo. Thus, they have high potential for clinical application.
  • SBPs serine senchymal stem cells
  • Muse cells are located sparsely in the connective tissue of dermis and adipose tissue and are not associated with any particular
  • Muse cells do not express the SKPs markers Snail and Slug (Wakao, et al. 2011). These data indicate that Muse cells are distinct from SKPs.
  • Muse cells in human dermal fibroblasts are readily differentiated into functional melanocytes by using certain combinations of factors and cytokines.
  • Muse cell-derived melanocytes (Muse-melanocytes ) expressed melanocyte markers such as microphthalmia- associated transcription factor (MITF) , tyrosinase-related protein 1 (TRP-1), dopachrome
  • Muse cells are an ideal cell source for generating functional melanocytes from adult human fibroblasts that can be applied to autologous or allogeneic transplantation for pigment disorders.
  • the Muse-melanocytes which express tyrosinase and produce melanin.
  • the Muse-melanocytes may further express at least one marker selected from the group consisting of DCT, Ki-67 and S100.
  • the Muse-melanocytes may be derived from Muse cells by use of two or more factors and/or cytokines selected from the group consisting of Wnt3a, stem cell factor (SCF) , endothelin-3 (ET-3), basic fibroblast growth factor (b-FGF) , linoleic acid, cholera toxin, L-ascorbic acid, 12-0-tetradecanoyl-phorbol 13- acetate (TPA) , insulin-transferrin-selenium (ITS), and dexamethasone .
  • SCF stem cell factor
  • ET-3 endothelin-3
  • b-FGF basic fibroblast growth factor
  • TPA 12-0-tetradecanoyl-phorbol 13-
  • the present invention provides a pharmaceutical composition comprising the Muse-melanocytes defined in the first embodiment.
  • the present invention provides the pharmaceutical composition in which naive Muse cells remain.
  • the present invention provides a three dimensional skin comprising the above Muse-melanocytes.
  • keratinocytes may be comprised in the three dimensional skin.
  • the present invention provides the three dimensional skin in which naive Muse cells remain.
  • the mesenchymal tissue may be a dermal tissue.
  • Muse cells may be separated from
  • the differentiation medium used in the above method may contain two or more factors and/or cytokines selected from the group consisting of Wnt3a, stem cell factor
  • SCF endothelin-3
  • b-FGF basic fibroblast growth factor
  • linoleic acid cholera toxin
  • L-ascorbic acid 12-0-tetradecanoyl-phorbol 13-acetate
  • TPA 12-0-tetradecanoyl-phorbol 13-acetate
  • ITS insulin-transferrin-selenium
  • subjects in need of such a treatment comprising applying the Muse-melanocytes according to the first embodiment, the pharmaceutical composition according to the second embodiment, or the three dimensional skin according to the third embodiment, to an affected area caused by the disorder.
  • Muse-melanocytes by differentiating Muse cells with two or more factors and/or cytokines selected from the group consisting of
  • Wnt3a stem cell factor (SCF) , endothelin-3 (ET-3) , basic fibroblast growth factor (b-FGF) , linoleic acid, cholera toxin, L-ascorbic acid, 12-O-tetradecanoyl-phorbol 13- acetate (TPA) , insulin-transferrin-selenium (ITS), and dexamethasone .
  • SCF stem cell factor
  • ET-3 endothelin-3
  • b-FGF basic fibroblast growth factor
  • TPA 12-O-tetradecanoyl-phorbol 13- acetate
  • ITS insulin-transferrin-selenium
  • FIG. 1 is data showing characterization of Muse cells .
  • b-f basic fibroblast growth factor
  • ET-3 endothelin-3
  • SCF stem cell factor
  • TPA 12-O-tetradecanoyl-phorbol 13- acetate
  • FIG. 2 is data showing morphology of Muse cells and non-Muse cells after differentiation, (a) Microscopic images of Muse cells and non-Muse cells before, and 3, 5, 6 weeks after the differentiation. Microscopic images of naive normal human dermal fibroblasts (NHDF) and human melanocytes are also provided (Scale bars: 100 ⁇ ) . (b) Enlarged images of Muse cells and non-Muse cells 6 weeks after the differentiation. Normal human melanocytes and NHDF are also shown.
  • NHDF normal human dermal fibroblasts
  • FIG. 3 is data showing characterization of Muse- melanocytes.
  • MITF microphthalmia- associated transcription factor
  • KIT KIT
  • TRP-1 tyrosinase-related protein 1
  • DCT dopachrome tautomerase
  • gplOO gplOO
  • the positive control was human melanocytes and the negative controls were naive normal human dermal fibroblasts
  • FIG. is data showing effect of factors on
  • MEF tyrosinase-related protein 1 ⁇
  • DCT dopachrome tautomerase
  • gplOO tyrosinase in Muse cells at 6 weeks of culture in 4 different media.
  • the positive control was human melanocytes and the negative control was no-template,
  • c Morphology of Muse cells in 4 different media at 6 weeks of culture. (Scale bars: 100 ⁇ ) .
  • FIG. 5 is data showing histologic analysis of 3D cultured skin, (a) Hematoxylin eosin (HE) staining of 3D cultured skin containing human melanocytes, Muse- melanocytes, non-Muse cells, and keratinocytes alone, (b) HE staining of the 3D cultured skin containing Muse- melanocytes. (Arrowheads indicate Muse-melanocytes).
  • HE Hematoxylin eosin
  • FIG. 6 is data showing functional characterization of Muse-melanocytes after transplantation into SCID mouse back skin, (a) Macroscopic observation of skin grafts containing Muse-melanocytes, human melanocytes, and keratinocytes only 10 days after transplantation, (b) Hematoxylin eosin staining of each skin graft (Scale bars: upper panels, 100 ⁇ , lower panels, 50 ⁇ ) .
  • FIG. 7 is data showing histologic analysis of three dimensional (3D) cultured human skin made by mixing naive
  • Muse cells with human keratinocytes for the epidermis (a) Localization of naive Muse cells labeled with green fluorescent protein (GFP) was observed in the epidermis (arrow) . (b) Immunohistochemical analysis of tyrosinase (TYR) , SlOO, and tyrosinase related protein-1 (TRP-1) in naive Muse cells labeled with GFP. The positive control was human melanocytes. (Scale bars: 50 ⁇ ) . Abbreviation:
  • FIG. 8 is data showing histologic analysis of three dimensional (3D) cultured skin made by including naive
  • TRP-1 tyrosinase related protein-1
  • FIG. 9 is data showing immunohistochemical analysis using anti Ki-67 antibody (Roche, Basel, Switzerland) and anti SlOO antibody in skin grafts containing Muse- melanocytes. Ki-67 expression was detected by an HPR-DAB system (brown color) (Wako, Osaka, Japan) . SlOO
  • HRP horseradish peroxidase
  • the present invention provides a pharmaceutical composition comprising melanocytes and keratinocytes, in which the melanocytes derived from multilineage- differentiating stress-enduring (Muse) cells by using certain combinations of factors and cytokines.
  • the present invention also provides a method of producing a three dimensional skin with Muse cells and a method of treating pigment disorder.
  • a pharmaceutical composition comprising Muse cell-derived melanocytes (i.e., Muse-melanocytes ) and keratinocytes
  • Muse-melanocytes are derived from Muse cells by use of two or more factors and/or cytokines, which include, but are not limited to, nt3a, stem cell factor (SCF), endothelin-3 (ET-3) , basic fibroblast growth factor (b-FGF) , linoleic acid, cholera toxin, L-ascorbic acid, 12-O-tetradecanoyl-phorbol 13-acetate (TPA) , insulin-transferrin-selenium (ITS), and dexamethasone .
  • cytokines include, but are not limited to, nt3a, stem cell factor (SCF), endothelin-3 (ET-3) , basic fibroblast growth factor (b-FGF) , linoleic acid, cholera toxin, L
  • keratinocytes optionally keratinocytes is provided.
  • dimensional skin may comprise any cells and/or proteins required for building the same.
  • a method of producing a three dimensional skin comprising the Muse- melanocytes and keratinocytes.
  • the method comprises the steps:
  • culturing the Muse cells in a differentiation medium containing two or more factors and/or cytokines which include, but are not limited to, nt3a, stem cell factor (SCF), endothelin-3 (ET-3) , basic fibroblast growth factor (b-FGF) , linoleic acid, cholera toxin, L- ascorbic acid, 12-O-tetradecanoyl-phorbol 13-acetate (TPA) , insulin-transferrin-selenium (ITS), and
  • a method of treating with pigment disorder in subjects in need of such a treatment comprising applying the above skin to an affected area caused by the disorder, is provided.
  • a method of obtaining Muse-melanocytes from Muse cells comprising the step of differentiating Muse cells with two or more factors and/or cytokines, which include, but are not limited to, Wnt3a, stem cell factor (SCF), endothelin-3 (ET-3), basic fibroblast growth factor (b-FGF) , linoleic acid, cholera toxin, L-ascorbic acid, 12-0-tetradecanoyl-phorbol 13-acetate (TPA) , insulin-transferrin-selenium (ITS), and dexamethasone.
  • cytokines include, but are not limited to, Wnt3a, stem cell factor (SCF), endothelin-3 (ET-3), basic fibroblast growth factor (b-FGF) , linoleic acid, cholera toxin, L-ascorbic acid, 12-0-tetradecanoyl-phorbol 13-acetate (TPA) , insulin-transfer
  • Muse cells used in the present inventions may be derived from dermal fibroblast or other mesenchymal tissues .
  • the present invention is . directed to use of Muse- melanocytes in regenerative medicine. Specifically, the present invention provides a pharmaceutical composition and a three dimensional skin for treating and/or
  • the term "pigment disorder” refers to conditions that cause the skin to appear lighter or darker than normal, or blotchy and discolored.
  • the pigment disorder includes albinism and vitiligo, which cause not only cosmetic problems but also increase the risk of skin cancers due to incomplete protection from UV rays.
  • the pigment disorder includes a skin burn, a scald, a scar of a burn, a wound and a keloid scar.
  • Muse- melanocytes can be obtained by differentiating Muse cells with specific, factors and/or cytokines.
  • Muse cells multilineage-differentiating stress- enduring cells
  • multilineage- differentiating stress-enduring (Muse) cells which are used for inducing melanocytes can be obtained from bone marrow fluid, adipose tissue (Ogura, F., et al., Stem
  • Muse cells Dev., Nov 20, 2013 (Epub) (published on Jan 17, 2014), or skin tissue such as dermis connective tissue or other mesenchymal tissues. Muse cells are scattered around connective tissues in organs. Further, Muse cells have both characteristics of pluripotent stem cells and mesenchymal cells, and, for example, they can be
  • SSEA-3 Stage-specific embryonic antigen- 3
  • CD105 double positive cells.
  • SSEA-3 and CD105 are cell surface markers of pluripotent stem cells and mesenchymal cells, respectively. Therefore, Muse cells or a cell population containing Muse cells can be separated from living tissues, for example, as a measure of these antigen markers. More detailed descriptions of a
  • pluripotent stem cells separated from the living mesenchymal tissues or cultured mesenchymal cells are also referred to as "SSEA-3 positive cells”.
  • non-Muse cells means cells contained in the living mesenchymal, tissues or cultured mesenchymal cells (other than “SSEA-3 positive cells”).
  • Muse cells or a cell population containing Muse cells can be separated from a living tissue (for example, a mesenchymal tissue) using an antigen against SSEA-3 or both antibodies against SSEA-3 and CD105.
  • a living tissue for example, a mesenchymal tissue
  • the term "living body” refers to a living mammalian body. The living body does not include fertilized eggs or embryos at development stages before the blastula stage, but include embryos at development stages on and after the blastula stage, such as fetuses and blastulae.
  • mammals include, but are not limited to, primates such as humans and monkeys, rodents such as mice, rats, rabbits, and guinea pigs, cats, dogs, sheep, pigs, cattle, horses, donkeys, goats, and ferrets.
  • rodents such as mice, rats, rabbits, and guinea pigs
  • Muse cells used in the pharmaceutical composition according to the present invention are clearly distinguished from
  • ES cells embryonic stem cells
  • EG cells iPS cells
  • muscle tissue refers to tissue such as bone, cartilage, fat, blood, bone marrow, skeletal muscle, dermis, ligament, tendon, dental pulp, umbilical cord, and cord blood, and tissue reside in each of organs.
  • Muse cells can be obtained from bone marrow, skin or adipose tissue. It is preferred to obtain a mesenchymal tissue from a living body and separate and utilize Muse cells from this tissue.
  • Muse cells may be separated from cultured mesenchymal cells such as fibroblasts or bone marrow stromal cells by use of the above separating method.
  • Muse cells used may be autologous or xenologous against recipients.
  • Muse cells can be separated, for example, using SSEA-3 positive marker or both SSEA-3 and CD105 double positive markers as an index.
  • SSEA-3 positive marker or both SSEA-3 and CD105 double positive markers as an index.
  • human adult dermis contains several types of stem cells and progenitor cells.
  • Muse cells are not identical to these cells.
  • stem cells and progenitor cells include skin-derived progenitor cells (SKPs), neural crest stem cells (NCSCs) ,
  • MBs melanoblasts
  • PCs perivascular cells
  • EPs endothelial progenitors
  • Muse cells can be separated using "non- expression" of markers specific to these cells as an index. Specifically, Muse cells can be isolated using non-expression of at least 1, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, markers selected from the group
  • CD34 (a marker of EP and ADSC)
  • CD271 (a marker of EP and ADSC)
  • NGFR a marker of NSCS
  • NG2 a marker of PC
  • vWF factor von Willebrand factor
  • SoxlO a marker of NCSC
  • Snail a marker of SKP
  • Slug a marker of SKP
  • Tyrpl a marker of MB
  • Dct a marker of MB
  • the separation can be performed using non-expression of CD117, CD146, NG2, CD34, vWF, and CD271 as an index. Moreover, the separation can be performed using non-expression of the above 11 markers as an index.
  • Muse cells having the above characteristics, which are used in the pharmaceutical composition may have at least one property selected from the group consisting of
  • Muse cells used in the present invention are (i) having low or no telomerase activity; (ii) having capability to differentiate into one of triploblastic cells; (iii) representing non-tumorigenic proliferation; and (iv) having self-renewal capability.
  • Muse cells used in the present invention are (i) having low or no telomerase activity; (ii) having capability to differentiate into one of triploblastic cells; (iii) representing non-tumorigenic proliferation; and (iv) having self-renewal capability.
  • Muse cells used in the present invention are Muse cells used in the present invention.
  • the expression "having no or low telomerase activity” refers to no or low telomerase activity being detected when such activity is detected using a TRAPEZE XL telomerase detection kit
  • Muse cells have capability to differentiate into triploblastic cells (ectodermal, mesodermal, and endodermal cell lineages) in vitro and in vivo, and they can differentiate into hepatocytes, neuronal cells, skeletal muscle cells, smooth muscle cells, bone cells and adipose cells. In addition, even when transplanted in the testis, Muse cells are capable of differentiating into triploblastic cells.
  • triploblastic cells ectodermal, mesodermal, and endodermal cell lineages
  • Muse cells are capable of migrating, surviving and differentiating into organs (e.g., skin, spinal cord, liver, and muscle) when transplanted to the damaged organs via intravenous injection into a living body.
  • organs e.g., skin, spinal cord, liver, and muscle
  • Muse cells have a property that they grow at a growth rate of about 1.3 days/cell
  • Muse cells have a property that they do not become cancerous for at least a half year.
  • Muse cells have self-renewal capability.
  • self-renewal refers to a situation in which cells contained in embryoid body-like cell clusters obtained by suspension culture of one Muse cell, can differentiate into triploblastic cells, and
  • next-generation embryoid body-like cell clusters can form by suspension culture of one cell contained in the previous embryoid body-like cell
  • Self-renewal may be performed by repeating a cycle once to several instances.
  • Muse cells can be differentiated into melanocytes (hereinafter referred to as "Muse-melanocytes" , if necessary), by use of a specific combination of factors and cytokines.
  • factors and cytokines include, but not limited to, Wnt3a, stem cell factor (SCF), endothelin-3 (ET-3) , basic fibroblast growth factor (b-FGF) , linoleic acid, cholera toxin, L-ascorbic acid, 12-O-tetradecanoyl-phorbol 13- acetate (TPA) , insulin- transferrin-selenium (ITS), and dexamethasone .
  • SCF stem cell factor
  • ET-3 endothelin-3
  • b-FGF basic fibroblast growth factor
  • TPA 12-O-tetradecanoyl-phorbol 13- acetate
  • ITS insulin- transferrin-selenium
  • Wnt3a refers to a member of WNT gene family consisting of structurally related genes that encode secreted signaling proteins.
  • SCF stem cell factor
  • E-3 endothelin-3
  • b-FGF basic fibroblast growth factor
  • b-FGF basic fibroblast growth factor
  • b-FGF basic fibroblast growth factor
  • cholera toxin refers to a protein complex secreted by the bacterium Vibrio cholerae .
  • L-ascorbic acid refers to a naturally occurring organic compound with antioxidant properties.
  • TPA tumor promoter
  • ITS insulin-transferrin-selenium
  • dimethasone refers to a potent synthetic member of glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. According to the present invention, the combination of the above factors and cytokines is not limited to
  • cytokines selected from the group consisting of nt3a, SCF, ET-3, b-FGF, linoleic acid, cholera toxin, L-ascorbic acid,
  • Muse cells can be differentiated into melanocytes, for example, as follows: Muse cells are cultured in differentiation medium containing 1-lOOOng/ml Wnt3a, 0.1-500ng/ml SCF, 0.1-lOOnM ET-3, 0.1-lOOng/ml b-FGF, 0.01-lOOmg/ml
  • the basic medium that is essential for survival of cells but is not limited to, a-Minimum
  • cc-MEM Dulbecco ' s Modified Eagle Medium
  • D- E Dulbecco ' s Modified Eagle Medium
  • BME Basal Medium Eagle
  • the above basic medium in which the above factors and/or cytokines are dissolved can be used as the
  • Muse cells are maintained in the differentiation medium for 1-12 weeks, and further such a melanocyte induction from Muse cells may be repeated at least 2 times, preferably at least 3 times.
  • the melanocyte induction may be carried out by adding the above factors and/or cytokines to the basic medium three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.
  • melanocyte-related markers in order to confirm that Muse cells have been differentiated into melanocyte (i.e., Muse-melanocyte has been obtained), the expression of melanocyte-related markers can be examined by various kinds of detection methods such as reverse transcription-polymerase chain reaction (RT-PCR) and FACS.
  • RT-PCR reverse transcription-polymerase chain reaction
  • the melanocyte-related markers include, but are not limited to, MiTF, c-kit, TRP-1, gplOO, DCT, and
  • the induced Muse cells express at least one of MiTF, c-kit, TRP-1, gplOO, DCT, and tyrosinase, the cells may be considered as Muse-melanocytes.
  • the pharmaceutical composition according to the present invention can be obtained, for example, by suspending the Muse-melanocytes and keratinocytes in a normal saline solution or an appropriate buffer such as a phosphate buffered saline (PBS) .
  • PBS phosphate buffered saline
  • the Muse-melanocytes or Muse cells may be grown in a cell medium until the desired number of cells.
  • a probability of canceration of the cells is low and can be safe, even when
  • undifferentiated cells obtained from a living tissue are contained in cell culture.
  • the pharmaceutical composition may contain, for example, DMSO and/or serum albumin for protection of the cells, and/or antibiotics for preventing the cells from contamination by bacteria.
  • various kinds of pharmaceutical acceptable components such as carriers, excipients, disintegrants , emulsifying agents, suspension agents, soothing agents, stabilizing agents, preserving agents, antiseptic agents and a normal saline solution, can be contained in the pharmaceutical composition.
  • the present invention provides a three dimensional skin comprising Muse-melanocytes.
  • the three dimensional skin can further comprise keratinocytes and extracellular matrix such as collagen, fibronectin, laminin, heparan sulfate proteoglycan and Matrigel ®.
  • a method of producing such a three dimensional skin comprising the steps:
  • a gel layer comprising extracellular matrix (e.g., collagen) and normal dermal fibroblast may be generated to mimic the dermis.
  • extracellular matrix e.g., collagen
  • Muse- melanocytes may be seeded onto the gel layer, optionally in combination with keratinocytes , and then they may be cultured until the desired tissue constructs can be obtained.
  • the three dimensional skin according to the present invention can be transplanted on model animals, and evaluated.
  • the evaluation of Muse cell pluripotency can be carried out, for example, by
  • compositions and methods are intended to mean that the compositions and methods include the recited elements, but not excluding others. "Consisting essentially of” when used to define
  • compositions and methods shall mean excluding other elements of any essential significance to the combination for the stated purpose.
  • a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic ( s ) of the claimed disclosure.
  • Consisting of shall mean excluding more than trace elements of other ingredients and
  • NHDF (Lonza, Walkersville, MD) were cultured in a - MEM (Invitrogen, Carlsbad, CA) containing 10% FBS
  • Humedia-KG2 medium Korean, Osaka, Japan
  • Muse cells and non-Muse cells were seeded separately at a density of 10,000 cells per 6-well plate and cultured for 1 day in a-MEM.
  • the cells were then cultured in differentiation medium containing 0.05 M dexamethasone (Sigma-Aldrich, St. Louis, MO), lx ITS (Invitrogen) , 1 mg/ml linoleic acid-bovine serum albumin (Sigma-Aldrich), 30% low-glucose DMEM, 20% MCDB-201 medium, 10 "4 M L-ascorbic acid (Sigma-Aldrich) , 50% DMEM conditioned by L-Wnt3a cells (American Type Culture
  • fibroblasts (NHDF, Lonza Walkersville, MD) were incubated with rat anti stage-specific embryonic antigen-3 (SSEA-3)
  • IgM antibody (1:50; Millipore, Billerica, MA; detected by fluorescein isothiocyanate-conjugated anti-rat IgM,
  • sorted Muse cells were individually plated in each well of 96-well ' plates . by limiting dilution of the cells with a-MEM (Invitrogen, Carlsbad, CA) , and cultured in single- cell suspension culture for 7 days. The dishes were coated with poly-HEMA (Sigma Aldrich, St. Louis, MO) to prevent cell-attachment. M-cluster formation was observed on Day 7. Alkaline Phosphatase (ALP) staining was then performed using a Leukocyte Alkaline Phosphatase kit (Sigma Aldrich) .
  • ALP Alkaline Phosphatase
  • M-clusters were transferred individually onto gelatin-coated dishes. After 7 days of culture, immunocytochemistry was performed as described previously (Kuroda et al, 2010). Antibodies used in this study were a-SMA (Lab Vision, Fremont, CA) , neurofilament (Chemicon, Millipore) , and GATA-4 (Abeam, Cambridge, UK) .
  • the L-Wnt3a cell line was obtained from American Type Culture Collection (Manassas, VA) .
  • L-Wnt3a cells were cultured in 10 cm dishes using high glucose DMEM (Invitrogen) containing 10% FBS (Hyclone; Thermo Fisher Scientific, Logan, UT) and 0.4mg/ml G418. After the cells grew to about 90% confluency, they were split 1:5 in 10 ml high glucose DMEM containing 10% FBS in 10 cm culture dishes and grown for 4 days. Then, the
  • conditioned medium in the dishes was collected and stored at 4° C after filtration with a 0.22 ⁇ filter. This was the first batch of medium.
  • 10 ml high glucose DMEM + 10% FBS was added to the dishes and cultured for another 3 days. After 3 days, the conditioned medium was collected and filtered. This was the second batch of medium. The first and second batches were mixed. This was the Wnt3a-conditioned medium which can be stored at 4° C for up to 4 weeks. The presence of Wnt3a protein in the conditioned media was checked by detecting the signal in a Western-blot analysis.
  • CDB201 medium was obtained from Sigma-Aldrich.
  • MCDB201 medium is a modification of Ham's nutrient mixture F-12, designed for the clonal growth of chicken embryo fibroblasts using hormones, growth factors, trace elements, and low levels of fetal bovine serum protein.
  • MCDB201 medium was used to make differentiation medium with DMEM and 10 differentiation- inducing factors.
  • PCR was performed as follows: one cycle at 94°C, 5 minutes, followed by 36 or 40 cycles at 94°C, 1 minute; gene-specific annealing temperature, 1 minute; 72°C, 1 minute; and then extension at 72°C, 7 minutes.
  • the primers were designed as follows: KIT forward primer, 5 ' -GAAAGTGACGTCTGGTCCTATGG-3 ' ; reverse primer, 5'- GTGCTCTCTGAAATCTGCTTCTCA-3 ' ; dopachrome tautomerase (DCT) forward primer, 5 1 -TCCTTCCTGAACGGGACAAA-3 ' ; reverse primer, 5 ' -TGGCATAGCTGTAGCCAAGTTG-3 ' ; MITF forward primer, 5 ' -CGGGAACAGGACCATGGTTA-3 1 ; reverse primer, 5'- AGCTAGCCCCTGAAATGAATCC-3 ' ; gplOO forward primer, 5'- CCAGTGTATCCCCAGGAAACTG-3 ' ; reverse primer, 5'--
  • phosphate buffered saline PBS
  • primary antibodies specific for MITF Lab Vision
  • tyrosinase Lab Vision
  • gplOO Dako, Carpinteria, CA
  • cells were incubated with secondary antibodies conjugated with Alexa Fluor 488 (Invitrogen) and counterstained with DAPI (Invitrogen) . Then they were examined using a clsi Nikon confocal microscope system (Nikon, Tokyo, Japan) .
  • keratinocytes at a ratio of 1:2.5 Muse-melanocytes to keratinocytes. They were incubated in Humedia KG2 medium (Kurabo) for 5 days with a gradually increasing Ca ++ concentration. The Ca ++ concentration was 0.15 mM on Day
  • 3D cultured skin and skin grafts were fixed with 10% formaldehyde, embedded in paraffin, and cut into 3- ⁇ thick sections. The sections were treated with 0.3% hydrogen peroxide in methanol for 12 minutes to
  • Skin grafts containing Muse-melanocytes labeled with GFP were fixed with freshly prepared periodate-lysine- paraformaldehyde for 6 hours at 4 ° C, embedded in OCT compound (Sakura Finetechnical , Tokyo, Japan) , and cut into 8- ⁇ thick cryosections .
  • the samples were washed with PBS and incubated with blocking solution at room temperature for 30 minutes.
  • the slides were then stained with anti-GFP antibody (Abeam) at 4°C overnight.
  • the slides were washed 3 times with PBS and incubated with secondary antibodies conjugated with Alexa Fluor 568
  • 3D cultured skins were grafted onto the back skin of 8 to 14-week-old SCID mice.
  • the mice were anesthetized with an intraperitoneal injection of tribromoethanol (Nacalai Tesque, Kyoto, Japan) and graft beds (8 mm x 8 mm) were prepared on the mouse back skin.
  • the 3D cultured skin was applied onto the graft beds and covered with Vaseline gauze, Steri-Strip ( 3M Company, St. Paul, MN) and a bandage. The bandage was removed on Day 3. Graft survival was observed for another 7 days.
  • Muse cells were infected with lentivirus containing green fluorescent protein (GFP) according to a previous report (Kuroda et al, 2010) , and then the cells were differentiated into Muse-melanocytes, subjected to 3D culture, and transplanted to the back skin of SCID mice.
  • GFP green fluorescent protein
  • the plasmids pMD.2G, pCMV-dR8.74, and pWPXL-GFP were kindly provided by Dr. Trono (Geneva, CH, Switzerland) .
  • High-titer GFP lentiviral supernatants were generated by transient co-transfection of the three plasmids in 293FT cells using Lipofectamine2000 (Invitrogen) and Opti-MEM I medium (GIBCO, Invitrogen) .
  • 293FT cells (90% to 95% confluency in a 100 mm dish) were transfected with 3 ⁇ g of pWPXL-EGFP, 3 g of pCMV-dR8.74, and 3 ⁇ g of pMD.2G.
  • Supernatants of transfected 293T cells were collected 2 and 3 days after transfection . The supernatants were filtered through 0.45 mm pore-size filters (Millipore) and were concentrated by using Amicon-U
  • NHDF was cultured in the mixed medium for 24 to 48 hours. Muse-GFP was isolated from NHDF-GFP as SSES-3/GFP double-positive cells using FACS.
  • Muse cells were collected from normal human dermal fibroblasts (NHDF, Lonza Walkersville, MD) . Because 100% of SSEA-3 positive cells from NHDF are positive for
  • Muse cell-derived cell cluster (M- clusters)
  • ALP alkaline phosphatase
  • Fig. lc expressed pluripotency markers such as Nanog, Oct 3/4, Sox2; and could self-renew, as
  • NHDF was separated into Muse and non-Muse cells by FACS and both were cultured separately in a specific differentiation medium containing 10 factors: Wnt3a, stem cell factor (SCF) , endothelin-3 (ET-3) , basic fibroblast growth factor (b-FGF) , linoleic acid, cholera toxin, L- ascorbic acid, 12-0- tetradecanoyl-phorbol 13-acetate (TPA) , insulin-transferrin- selenium (ITS), and
  • dexamethasone (Fig. lg) .
  • the morphology of the Muse cells began to change and cells with dendrites appeared within 3 weeks. Cell size was slightly reduced by 5 weeks, and by 6 weeks, the cells had morphology similar to that of human melanocytes (Fig. 2) . Such changes did not occur in non-Muse cells, however, and most of the . non-Muse cell- derived cells remained fibroblast-like, even after 6 weeks of differentiation (Fig. 2).
  • melanocyte-related markers was examined in Muse-melanocytes and non-Muse cell-derived cells after 6 weeks of differentiation. Human melanocytes were used as a positive control. In reverse
  • RT-PCR transcription-polymerase chain reaction
  • tyrosinase gplOO, and MITF were detected in Muse- melanocytes (6 weeks), as in the case of human
  • Muse-melanocytes were further evaluated by the L- DOPA reaction assay to examine melanin productivity. Many cells were positive for the L-DOPA reaction assay (Fig. 3c) . These results suggested that cells with
  • Muse cells cultured in media 5 and 6 did not proliferate well and all of them died within 20 days (Fig. 4a) .
  • Muse cells cultured in media 1 and 2 expressed only MITF and/or KIT. In media 3, 4, and 7, Muse cells
  • the spontaneous differentiation potential of Muse cells in the 3D cultured skin was also examined.
  • GFP green fluorescent protein
  • naive Muse cells undifferentiated Muse cells
  • keratinocytes to construct the epidermis of the 3D cultured skin.
  • GFP-positive naive Muse cells were identified in the epidermis but none of them expressed melanocyte markers S100, TRP-1, or tyrosinase (Fig. 7a-b) . This result indicated naive Muse cells do not spontaneously differentiate into melanocytes even if they are
  • 3D cultured human skin model reflects the physiological situation of human melanocytes in human skin more accurately than the experiment by using mouse skin (Haake and Scott, 1991; Meier et al, 2000), we used 3D cultured skin to evaluate the migration potential of naive Muse cells and Muse- melanocytes.
  • GFP-positive naive Muse cells or Muse- melanocytes mixed with NHDF were embedded into the dermal equivalent of 3D cultured skins and then seeded human keratinocytes only on top of the dermal equivalent.
  • Fig. 8a GFP-labeled naive Muse cells were detected in the epidermis of 3D cultured skin (Fig. 8a), although they did not express S100, TRP-1, or tyrosinase, as stated above (Fig. 7) .
  • Some of the Muse-melanocytes migrated from the dermal equivalent, integrated into the epidermal layer, and expressed S100 and TRP-1 (Fig. 8b), showing that Muse-melanocytes have the potential of migrating into the epidermis where human melanocytes normally reside.
  • FIG. 6a, b Histologic evaluation revealed that skin grafts with Muse-melanocytes contained
  • Muse-melanocytes located in the basal layer that were brown in color (Fig. 6a, b) , and immunohistochemical analysis revealed that they were positive for MITF, tyrosinase, TRP-1, gplOO, and S100, the same as grafted human melanocytes (Fig. 6c) . Furthermore, Muse- melanocytes and the neighboring keratinocytes were positive for Fontana-Masson staining, as seen in human melanocytes (Fig. 6c).
  • DPSCs a mesenchymal stem cell type, are reported to differentiate into melanocytes (Stevens et al, 2008;
  • Paino et al, 2010) Stevens et al successfully induced cells that expressed the melanocyte marker, melanoma antigen, recognized by T-cells 1 (Mart-1) from CD34 (- )/CD271(+) DPSCs. Although Muse cells in NHDF are also CD3 (-) , they might be distinct from dental pulp cells because NHDF-derived Muse cells are negative for CD271, as reported previously. Paino et al reported that DPSCs spontaneously differentiate into melanocytes without any stimulation. The spontaneously differentiated cells express DCT, TRP-1, and Mart-1, and are positive for the melanocyte marker, melanoma antigen, recognized by T-cells 1 (Mart-1) from CD34 (- )/CD271(+) DPSCs. Although Muse cells in NHDF are also CD3 (-) , they might be distinct from dental pulp cells because NHDF-derived Muse cells are negative for CD271, as reported previously. Paino et al reported that
  • melanocytes can be induced from ES cells and iPS cells
  • melanocytes like Muse-melanocytes , express several melanocyte-related markers containing tyrosinase and produce melanin in 3D cultured skin.
  • the techniques for inducing melanocytes from Muse cells are important in relation to the clinical application.
  • ES cells and iPS cells increase the risk for tumorigenesis ( Fong et al, 2010; Goldring et al, 2011; Ben-David et al, 2011; Okita et al, 2007), while MSCs, which contain Muse cells, have a low risk of tumorigenesis and have already been applied to patients in many clinical trials (Kuroda et al, 2011).
  • Muse cells have a property that they do not become cancerous, both differentiated Muse- melanocytes and Muse cells that have not been
  • differentiated into melanocytes can be used for the following reasons
  • ES cells are obtained from fertilized eggs, treating ES cells requires much more effort and poses more ethical problems (Knoppers et al, 2009; Manzar et al, 2011).
  • iPS cells are obtained from somatic cells such as fibroblasts, so the ethical problems are avoided, but they require artificial gene transduction to generate pluripotent stem cells (Takahashi et al, 2006; Takahashi et al, 2007).
  • Muse cells on the other hand, normally reside in accessible mesenchymal tissue such as the dermis and in commercially available fibroblasts, so that they are an attractive cell source for clinical and industrial uses. In addition, Muse cells are easily isolated from mesenchymal cells by simple labeling with
  • Muse cells can be obtained from accessible mesenchymal tissues, autologous or allogeneic transplantation of Muse-melanocytes can also be expected.
  • DCT Human melanocyte stem cells are known to reside in hair follicles, have self-renewal capacity, and play a role for maintaining the number of melanocytes in the epidermis. Both DCT and PAX3 were known as markers of melanocyte stem cells. We have demonstrated DCT
  • the Wnt3a, ET-3, SCF, b-FGF, and cAMP inducers
  • transcription factors PAX3, SOX10, CREB, LEF1 through intracellular signaling Steingrimsson et al, 2004, Dong et al, 2012, Kondo et al, 2011.
  • MITF-M which is one of the MITF variants specific for melanocytes and has a crucial role in melanocyte differentiation
  • Wnt3a, ET-3, SCF, b-FGF and cAMP inducers in the. differentiation medium are considered to induce
  • Muse cells were cultured in medium lacking any of those three factors, they expressed very few melanocyte-related markers and their morphology was different ⁇ from that of authentic melanocytes.
  • Muse cells cultured in medium containing only those three factors expressed MITF, KIT, TRP-1, DCT, and gplOO, but not tyrosinase, suggesting that while, these three factors are preferable for differentiation into melanocytes, additional
  • differentiation- enhancing factors such as cholera toxin, TPA, and linoleic acid may be used in order to
  • Vitiligo a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 65:473-91.
  • Vitiligo a comprehensive overview Part II: treatment options and approach to treatment. J Am Acad Dermatol 65: 493-51 .
  • Multipotent cell fate of neural crest-like cells derived from embryonic stem cells Stem Cells 25:402-10.
  • mesenchymal stem/multipotent stromal cells the state of transdifferentiation and modes of tissue repair—current views. Stein Cells 25:2896-902.
  • Multilineage-differentiating str.ess-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts. Proc Natl Acad Sci U S A 108:9875-80.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
PCT/JP2014/060045 2013-04-02 2014-04-01 Use of functional melanocytes readily differentiated from multilineage-differentiating stress-enduring (Muse) cells, distinct stem cells in human fibroblasts WO2014163206A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015548081A JP2016516394A (ja) 2013-04-02 2014-04-01 ヒト線維芽細胞において特徴的な幹細胞であるＭｕｓｅ細胞から容易に分化した機能性メラノサイトの使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361807465P 2013-04-02 2013-04-02
US61/807,465 2013-04-02

Publications (1)

Publication Number Publication Date
WO2014163206A1 true WO2014163206A1 (en) 2014-10-09

Family

ID=51658491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/060045 WO2014163206A1 (en) 2013-04-02 2014-04-01 Use of functional melanocytes readily differentiated from multilineage-differentiating stress-enduring (Muse) cells, distinct stem cells in human fibroblasts

Country Status (2)

Country Link
JP (1) JP2016516394A (enrdf_load_stackoverflow)
WO (1) WO2014163206A1 (enrdf_load_stackoverflow)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081570A1 (en) * 2014-11-18 2016-05-26 The Trustees Of The University Of Pennsylvania Compositions and methods for the generation of melanocytes through direct reprogramming
JP2018518970A (ja) * 2015-06-22 2018-07-19 ナショナル ユニヴァーシティ オブ シンガポール 血管新生化組織、皮膚、又は粘膜等価物
CN111330066A (zh) * 2020-04-30 2020-06-26 西安交通大学医学院第一附属医院 一种面向重症患者皮损修复的三维结构化生物敷料
EP3643316A4 (en) * 2017-06-19 2021-01-20 National University Corporation Hokkaido University TREATMENT PRODUCTS FOR EPIDERMOLYSIS BULLOSA
CN117187174A (zh) * 2023-11-08 2023-12-08 广州正源生物技术有限公司 一种Muse细胞培养基以及一种脂肪Muse细胞的提取方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023041486A (ja) * 2021-09-13 2023-03-24 国立大学法人東北大学 毛髪損傷の治療剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104200A1 (en) * 2010-02-23 2011-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing human melanocytes from human pluripotent stem cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104200A1 (en) * 2010-02-23 2011-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing human melanocytes from human pluripotent stem cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FANG,D. ET AL.: "Defining the conditions for the generation of melanocytes from human embryonic stem cells.", STEM CELLS, vol. 24, no. 7, July 2006 (2006-07-01), pages 1668 - 77 *
KURODA,Y. ET AL.: "Unique multipotent cells in adult human mesenchymal cell populations.", PROC. NATL. ACAD. SCI. USA, vol. 107, no. 19, 11 May 2010 (2010-05-11), pages 8639 - 43 *
NISSAN, X. ET AL.: "Functional melanocytes derived from human pluripotent stem cells engraft into pluristratified epidermis.", PROC. NATL. ACAD. SCI. USA, vol. 108, no. 36, 6 September 2011 (2011-09-06), pages 14861 - 6 *
OHTA,S. ET AL.: "Generation of human melanocytes from induced pluripotent stem cells.", PLOS ONE, vol. 6, no. 1, 13 January 2011 (2011-01-13), pages E16182 *
PAINO, F. ET AL.: "Ecto-mesenchymal stem cells from dental pulp are committed to differentiate into active melanocytes.", EUR. CELL . MATER., vol. 20, 7 October 2010 (2010-10-07), pages 295 - 305 *
TSUCHIYAMA,K. ET AL.: "Functional melanocytes are readily reprogrammable from multilineage-differentiating stress-enduring (muse) cells, distinct stem cells in human fibroblasts.", J. INVEST. DERMATOL., vol. 133, no. 10, October 2013 (2013-10-01), pages 2425 - 35 *
WAKAO,S. ET AL.: "Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts.", PROC. NATL. ACAD. SCI. USA, vol. 108, no. 24, 14 June 2011 (2011-06-14), pages 9875 - 80 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081570A1 (en) * 2014-11-18 2016-05-26 The Trustees Of The University Of Pennsylvania Compositions and methods for the generation of melanocytes through direct reprogramming
CN107530378A (zh) * 2014-11-18 2018-01-02 宾夕法尼亚州立大学托管会 通过直接重编程生成黑色素细胞的组合物和方法
US10844352B2 (en) 2014-11-18 2020-11-24 The Trustees Of The University of Pennsyivania Compositions and methods for the generation of melanocytes through direct reprogramming
JP2018518970A (ja) * 2015-06-22 2018-07-19 ナショナル ユニヴァーシティ オブ シンガポール 血管新生化組織、皮膚、又は粘膜等価物
EP3643316A4 (en) * 2017-06-19 2021-01-20 National University Corporation Hokkaido University TREATMENT PRODUCTS FOR EPIDERMOLYSIS BULLOSA
CN111330066A (zh) * 2020-04-30 2020-06-26 西安交通大学医学院第一附属医院 一种面向重症患者皮损修复的三维结构化生物敷料
CN111330066B (zh) * 2020-04-30 2022-05-20 西安交通大学医学院第一附属医院 一种面向重症患者皮损修复的三维结构化生物敷料
CN117187174A (zh) * 2023-11-08 2023-12-08 广州正源生物技术有限公司 一种Muse细胞培养基以及一种脂肪Muse细胞的提取方法
CN117187174B (zh) * 2023-11-08 2024-02-06 广州正源生物技术有限公司 一种Muse细胞培养基以及一种脂肪Muse细胞的提取方法

Also Published As

Publication number Publication date
JP2016516394A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
Tsuchiyama et al. Functional melanocytes are readily reprogrammable from multilineage-differentiating stress-enduring (muse) cells, distinct stem cells in human fibroblasts
JP4146802B2 (ja) 単球を起源に持つ、脱分化したプログラム可能な幹細胞およびそれらの製造と使用
KR20110022713A (ko) 인간 만능줄기세포로부터 인간 피부 대체물을 제조하는 방법
JP2018203780A (ja) 生体組織から単離できる多能性幹細胞
CA2867953C (en) Regulating stem cells
US7176023B2 (en) Endothelial cells derived from primate embryonic stem cells
KR20120120971A (ko) 인간 다능성 줄기 세포로부터 인간 멜라닌세포를 제조하는 방법
US20240002811A1 (en) Methods for Generation for Pluripotent and Multipotent Cells
JP2011525370A5 (enrdf_load_stackoverflow)
WO2014163206A1 (en) Use of functional melanocytes readily differentiated from multilineage-differentiating stress-enduring (Muse) cells, distinct stem cells in human fibroblasts
WO2012040465A2 (en) Multipotent stem cells and uses thereof
WO2012133948A1 (ja) 生体組織から単離できるssea-3陽性の多能性幹細胞を含む他家移植用細胞治療用組成物
DE60300681T2 (de) Dedifferenzierte, programmierbare stammzellen monozytären ursprungs, sowie deren herstellung und verwendung
JP2015097524A (ja) 再構成皮膚の作製用の組成物および方法
Yonetani et al. In vitro expansion of immature melanoblasts and their ability to repopulate melanocyte stem cells in the hair follicle
EP2898065B1 (en) Adipose tissue cells
TW202340454A (zh) 將誘導性多能幹細胞分化為視網膜色素上皮細胞之方法、視網膜色素上皮細胞以及使用該視網膜色素上皮細胞之方法
WO2010068758A1 (en) Somatic cell-derived pluripotent cells and methods of use therefor
WO2012071108A1 (en) Somatic cell-derived pluripotent cells and methods of use therefor
JP2005287478A (ja) ヒト脂肪前駆細胞株及びその利用方法
Shamis hESC-and iPSC-Derived Fibroblasts for Skin Engineering and Repair
CN118234847A (zh) 胸腺细胞和制备方法
Meador Derivation of endothelial colony forming cells from human cord blood and embryonic stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14778547

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015548081

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 13.01.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14778547

Country of ref document: EP

Kind code of ref document: A1